ACM
IONS icon

Asymmetry Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Asymmetry Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37,021
Closed -$1.91M – 26
2018
Q3 		$1.91M Buy
+37,021
New +$1.74M 1.76% 25
2017
Q4 		– Sell
-55,965
Closed -$2.84M – 34
2017
Q3 		$2.84M Buy
+55,965
New +$2.93M 3.29% 13

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Asymmetry Capital Management's IONS Position: Q4 2018 in Review

Asymmetry Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 37,021 shares — an estimated $1.91M sold.

Asymmetry Capital Management first reported a position in IONS in Q3 2017 and held it in 2 quarters. The position peaked at $2.84M in Q3 2017. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

  • Asymmetry Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 37,021 Ionis Pharmaceuticals shares in Q4 2018, an estimated $1.91M.
  • Asymmetry Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Asymmetry Capital Management's Ionis Pharmaceuticals position peaked at $2.84M in Q3 2017.
  • 329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on Asymmetry Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.